ArticleCellular and molecular life sciences : CMLS2025
STK32C promotes colon tumor progression through activating c-MYC signaling.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Serine/threonine kinase 32C (STK32C) is a member of the AGC kinase family and has been identified as a potential promoter of cancer progression, though its role remains largely uncharacterized. This study explores the impact of STK32C on colorectal cancer (CRC) progression, particularly focusing on its influence on the MYC signaling pathway. Analysis of CRC samples and in vitro experiments revealed that STK32C expression is significantly elevated in cancerous tissues and associated with poor prognosis. Functional assays demonstrated that STK32C promotes proliferation, migration, and invasion of CRC cells, likely through phosphorylation of MYC at the S420 site, enhancing MYC stability and signaling activity. In vivo studies using a mouse xenograft model confirmed that STK32C knockdown suppresses tumor growth and MYC pathway activation. These findings suggest that STK32C contributes to CRC progression by modulating MYC signaling, highlighting its potential as a therapeutic target in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.